Evidence map›Paper›PMID 42773142›Full record

ArticleNature communications2026

Structural basis of lenacapavir-induced HIV-1 capsid defects during virion maturation.

Hiroki Tanaka, Reina Morita, Tomomasa Oka, Minoru Fukushima, Shunsuke Kita, Mina Sasaki, Katsumi Maenaka, Shinichi Machida

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroki TanakaDepartment of Structural Virology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Reina MoritaDepartment of Structural Virology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Tomomasa OkaDepartment of Structural Virology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Minoru FukushimaDepartment of Structural Virology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Shunsuke KitaLaboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID http://orcid.org/0000-0003-3969-302X
Mina SasakiLaboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID http://orcid.org/0009-0006-6743-8789
Katsumi MaenakaLaboratory of Biomolecular Science, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.ORCID http://orcid.org/0000-0002-5459-521X
Shinichi MachidaDepartment of Structural Virology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan. machida.s@jihs.go.jp.ORCID http://orcid.org/0009-0002-8891-4888

Funding

Japan Agency for Medical Research and Development (AMED) JP22ama121037Japan Agency for Medical Research and Development (AMED) JP243fa627005Japan Agency for Medical Research and Development (AMED) JP25fk0310527Japan Agency for Medical Research and Development (AMED) JP25fk0310530Japan Agency for Medical Research and Development (AMED) JP25fk0310547Japan Agency for Medical Research and Development (AMED) JP25fk0410078MEXT | Japan Society for the Promotion of Science (JSPS) JP20H05873MEXT | Japan Society for the Promotion of Science (JSPS) JP25K02504
6 · The paper itself

Abstract

Long-acting lenacapavir (LEN) has emerged as a highly effective, potentially game-changing therapy for HIV treatment and prevention. Its mechanism of action in the early phase of HIV-1 replication, when the capsid directs key post-entry steps such as reverse transcription, nuclear import, and integration, has been well characterized. In contrast, its effects during the late phase of replication, when the capsid assembles and matures within budding virions, remain poorly understood. Here, we determine the cryo-electron microscopy structure of the mature HIV-1 capsid lattice assembled within virus-like particles in the presence of LEN. Our structural analyses reveal that LEN alters interhexamer interactions, perturbs the capsid lattice curvature, and thereby prevents the formation of a functional cone-shaped capsid. Biochemical analyses further demonstrate that LEN-containing cores lose reverse transcriptase because of compromised capsid integrity, whereas integrase and viral RNA remain associated. Functionally, viruses produced in the presence of LEN exhibit markedly reduced infectivity, low reverse transcription activity, and poor integration. Taken together, these findings provide mechanistic insights into the late-phase action of LEN and provide key directions for the design of future inhibitors.

Indexed as

Anti-HIV AgentsCapsidHIV-1QuinolonesVirionAcetamidesCapsid ProteinsCryoelectron MicroscopyHIV Reverse TranscriptaseHumansIndazolesReverse TranscriptionRNA, ViralVirus AssemblyVirus IntegrationVirus ReplicationAcetamidesAnti-HIV AgentsCapsid ProteinsHIV Reverse TranscriptaseIndazoleslenacapavirQuinolonesRNA, Viral

Identifiers

PMID42773142
PMCPMC13598136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.